At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
Tarceva (Erlotinib hydrochloride) +1 moredrug
Likely dose
Tarceva (Erlotinib hydrochloride) 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Determine the Efficacy of Tarceva® (Erlotinib Hydrochloride) With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Tarceva (Erlotinib hydrochloride) and Radiation Therapy for Non-small Cell Lung Cancer and Brain Cancer. Completed, enrolled 44 participants across 2 sites.
Detailed Summary
The goal of this clinical research study is to learn whether Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy, is better to treat brain metastases in patients with Non-Small Cell Lung Cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Brain Cancer
CountriesUnited States
CollaboratorsOSI Pharmaceuticals
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMar 2009
Primary CompletionDec 2019
TodayJul 2026
First PostedMar 30, 2009
Enrollment StartMar 26, 2009
Primary CompletionDec 4, 2019
TodayJul 2, 2026
Enrollment to primary: 10.7 yearsPosted 17.3 years ago
Interventions
Tarceva (Erlotinib hydrochloride)drug
150 mg by mouth every day beginning Day 1.
Radiation Therapyradiation
Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.